AstraZeneca’s AKT inhibitor capivasertib reaches U.K. market

The UK Medicine and Healthcare products Regulatory Agency (MHRA) has approved AstraZenica and Astex Pharmaceuticals’ AKT inhibitor, capivasertib. The drug, designed to treat HR+/HER2-breast cancer, inhibits the PI3K/AKT/mTOR signalling pathway, often dysregulated in cancers. Approved by the US FDA last November, capivasertib also demonstrated promise in phase 3 clinical trials, resulting in progression-free survival of 7.3 months versus 3.1 months for the placebo group. The approval potentially marks a significant step for AKT inhibitors in oncology.